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Arctigenin (ARC) is a lignan and is abundant in Asteraceae plant which possesses 
anti-inflammatory and anti-cancer activities. The current study was performed to 
investigate if ARC affects cancer progression and metastasis focusing on epithelial–
mesenchymal transition (EMT) using invasive human lung cancer cell line, A549. No 
toxicity was observed in the cells treated with different doses of ARC (12-100 µM). 
The treatment of ARC repressed TGF-β-stimulated changes of metastatic morphology 
and cell invasion and migration. ARC inhibited TGF-β-induced phosphorylation and 
transcriptional activity of SMAD2/3 and expression of snail in dose-dependent and 
time-dependent manners. ARC also decreased expression of N-cadherin and increased 
expression of E-cadherin in dose-dependent and time-dependent manners. These 
changes were accompanied with decreased amount of nuclear phospho-SMAD2 and 
SMAD3, and nuclear translocation of SMAD2 and SMAD3. Moreover, ARC repressed 
TGF-β-induced phosphorylation of ERK. Our data demonstrate anti-metastatic activity 
of ARC in lung cancer model. 
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Chapter 1: Background 
1.1 Lung cancer overview 
Lung cancer, also known as lung carcinoma, is a malignant lung 
tumor characterized by uncontrolled cell growth in tissues of lungs. This growth can 
spread beyond the lung by the process of metastasis into nearby tissue or other parts of 
the body [1]. Most cancers that start in the lung, known as primary lung cancers, 
are carcinomas. The two broad histological subtypes of lung cancer are small-cell lung 
cancer (SCLC), which is the cause of 15% of cases, and non-small-cell lung 
cancer (NSCLC), which accounts for 85% of cases and includes adenocarcinoma, 
squamous-cell carcinoma and large-cell carcinoma [2]. The most 
common symptoms of lung cancer are coughing (including coughing up blood), weight 
loss, shortness of breath, and chest pains [3]. Worldwide in 2012, lung cancer occurred 
in 1.8 million people and resulted in 1.6 million deaths [4]. This makes it the most 
common cause of cancer-related death in men and second most common in women 
after breast cancer [4]. 
Treatment option for lung cancer depends on the cancer's specific cell type, how 
far it has spread, and the person's performance status. Common treatments 
include palliative care, surgery, chemotherapy, and radiation therapy. However, in 
many cases that the cancer cells have widely spread, surgery is no longer available. 
Furthermore, during the process of chemotherapy and radiotherapy, there exists severe 
side effects including fatigue, hair loss, easy bleeding, infection, anemia, nausea and 
vomiting [5, 6]. Therefore, new therapy against human lung cancer with less side effects 





Metastasis is one of the hallmarks of cancer, distinguishing it from benign tumors 
[7], and plays an important role in the malignancy and poor prognosis of cancer. It is a 
complex process whereby cancer cells spread from a primary organ site and form 
tumors at distant organ sites. During this process, some cancer cells known 
as circulating tumor cells acquire the ability to penetrate the walls 
of lymphatic or blood vessels by loss of cell-cell and cell-matrix adhesion, increased 
cellular motility and invasion [8], after which they are able to circulate through the 
bloodstream to other sites and tissues in the body. This process is known 
as lymphatic or hematogenous spread. After the tumor cells come to rest at another site, 
they re-penetrate the vessel or walls and continue to multiply, eventually forming 
another clinically detectable tumor. This new tumor is known as a metastatic 
tumor. Most cancers can metastasize, although in varying degrees. 
Metastasis is a key element in cancer staging systems such as the TNM, where it 
represents the "M". In overall stage grouping, metastasis places a cancer in Stage IV. 
The possibilities of curative treatment are greatly reduced, or often entirely removed, 
when a cancer has metastasized. Therefore, around 90% of all cancer deaths are the 
result of metastases, rather than of the primary tumors [9]. 
Lung cancer, which is one of the most common and malignant cancers worldwide, 
is most often diagnosed at late stages, when it has already presented local invasion and 
distal metastases. The cascade of events during lung cancer metastasis include: (1) 
Detachment of tumor cells from the extracellular matrix (ECM) and degradation of the 
ECM by several proteolytic enzymes. (2) Invasion of neighboring tissues and basement 




on the endothelial cells with adhesion molecules, infiltration of the vessels, survival 
and transport through the blood stream. (4) Arrest and extravasation at a distal site and 
formation of a metastatic lesion. Research in past decades highlighted the steps of 
metastasis at a microscopic level. However, this had little or no effects on improving 
treatment outcome, since still almost 90% of lung cancer patient deaths are metastasis-
related. Therefore, further research of novel and more effective strategies for preventing 
and treating lung cancer is still needed [10]. 
1.3 Epithelial–Mesenchymal Transition (EMT) 
The epithelial-mesenchymal transition (EMT) is a process by which 
epithelial cells lose their cell polarity and cell-cell adhesion, and gain migratory and 
invasive properties to become mesenchymal stem cells [8]. It is an important cellular 
process during embryonic morphogenesis, organogenesis and tissue repair and 
remodeling [11], and it also plays an important role in the initiation of metastasis in 
cancer progression [12]. 
EMT was first recognized as a feature of embryogenesis by Betty Hay in the 1980s 
[13, 14]. EMT, and its reverse process, MET (mesenchymal-epithelial transition) are 
critical for development of many tissues and organs in the developing embryo, and 
numerous embryonic events such as gastrulation, neural crest formation, heart 
valve formation, palatogenesis and myogenesis [15]. Epithelial and mesenchymal cells 
differ in phenotype as well as function, though both share inherent plasticity [14]. 
Epithelial cells are closely connected to each other by tight junctions, gap 
junctions and adherens junctions, have an apico-basal polarity, polarization of 
the actin cytoskeleton and are bound by a basal lamina at their basal surface. On the 




morphology and interact with each other only through focal points [16]. Epithelial cells 
express high levels of E-cadherin, whereas mesenchymal cells express those of N-
cadherin, fibronectin and vimentin. Thus, EMT entails profound morphological and 
phenotypic changes to the cells. 
TGF-β is a multifunctional cytokine and most well-known EMT stimulant [17]. 
TGF-β-treated cells in vitro undergo mesenchymal-like spindle-shaped morphology 
with a decrease in cell-cell and cell-matrix adhesion and loss of polarity [18]. Regarding 
to cellular and molecular event, TGF-β first binds to type II receptor which leads to 
recruitment and phosphorylation of the type I receptor. The activated type I receptor 
subsequently induces phosphorylation of SMAD2 and SMAD3 (R-SMADs) and form 
heterodimeric complexes with a SMAD4 (co-SMAD). The complex of SMAD2/3/4 
trans-locates into the nucleus and binds to SMAD response element (SRE) on the 
promoter of their specific target genes, and mediates EMT [19]. Additionally, TGF-β 
activates non-SMAD signaling pathways such as extracellular-regulated kinase (ERK), 
p38 MAPK, and c-Jun N-terminal kinase (JNK) during signal transduction of TGF-β-
induced cell migration and invasion [20]. 
1.4 E-cadherin 
E-cadherin is one of the most important molecules in cell-cell adhesion in 
epithelial tissues. It is localized on the surfaces of epithelial cells in regions of cell-cell 
contact known as adherens junctions [21]. E-cadherin molecules are critical for the 
formation and maintenance of adherent junctions in areas of epithelial cell-cell contact, 
and it also plays a major role in malignant cell transformation, and especially in tumor 
development and progression. The suppression of E-cadherin expression is regarded as 




tumors have abnormal cellular architecture, and loss of tissue integrity can lead to local 
invasion. Thus, loss of function of E-cadherin tumor suppressor protein correlates with 
EMT and increases invasiveness and metastasis of tumors [22]. 
1.5 N-cadherin 
N-cadherin is encoded by the CDH2 gene [23] and expressed in multiple tissues 
and functions to mediate cell–cell adhesion. N-cadherin is associated with a lot of 
molecules that regulate its function. It is involved in a lot of processes like cell-cell 
adhesion, differentiation, embryogenesis, migration, invasion and signal transduction. 
During EMT, the aberrant expression of N-cadherin attributes a more fibroblastic 
phenotype to the cancer cells, and as a result, the cells become more motile and invasive 
[24]. 
1.6 Snail 
Snail is a protein that is encoded by the SNAI1gene [25]. It is a family of 
transcription factor that promotes the repression of the adhesion molecule E-cadherin 
to regulate EMT during embryonic development. As a critical regulator of multiple 
signaling pathways leading to EMT, the expression of Snail is closely associated with 
cancer metastasis. It has been demonstrated that Snail is required for lymph node 
metastasis of human breast carcinoma MDA-MB-231 cells [26]. A set of genes of the 
“lung metastasis signature” are direct or indirect targets of Snail. They include ID1, 
SPARC or MMP2 [27]. It has also been observed that the level of expression of Snail 
is elevated in metastatic lesions in ovarian cancer [28]. A recent study demonstrated 
that Snail-induced EMT accelerates metastasis through induction of immune-




metastasis by increasing tumor-infiltrating lymphocytes and systemic immune 
responses [29]. Therefore, Snail is an effective target for preventing metastasis. 
1.7 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF), originally known as vascular 
permeability factor (VPF), is a signal protein produced by cells that stimulates the 
formation of blood vessels. To be specific, VEGF is a sub-family of growth factors, 
the platelet-derived growth factor family of cystine-knot growth factors. They are 
important signaling proteins involved in both vasculogenesis (the de novo formation of 
the embryonic circulatory system) and angiogenesis (the growth of blood vessels from 
pre-existing vasculature) [30]. 
VEGF family stimulate cellular responses by binding to tyrosine kinase receptors 
(the VEGFRs) on the cell surface, causing them to dimerize and become activated 
through transphosphorylation, although to different sites, times, and extents. The VEGF 
receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a 
single transmembrane spanning region, and an intracellular portion containing a 
split tyrosine-kinase domain [31]. 
VEGF's normal function is to create new blood vessels during embryonic 
development, new blood vessels after injury, muscle following exercise, and new 
vessels (collateral circulation) to bypass blocked vessels. When VEGF is overexpressed, 
it can contribute to diseases such as cancer. Solid cancers cannot grow beyond a limited 
size without an adequate blood supply, however, cancers that can express VEGF are 
able to grow and metastasize. It is reported that VEGF family members play an 
important role in the development of pancreatic cancer [32], and EMT confers efficient 




proangiogenic factor VEGF-A and by increased tumor angiogenesis [33]. At the same 
time, VEGF mediates promotion of human ovarian cancer cell invasion [34]. Some 
other researcher also pointed out that high expression of VEGF is associate with poor 
prognosis of gastric cancer [35]. Meanwhile, VEGF is also involved in the treatment of 
certain cancers. It has been reported that the anti-tumor effect is enhanced by targeting 
VEGF in colorectal cancer [36]. 
1.8 Cyclin D1 
Cyclin-D1 is a protein that in humans is encoded by the CCND1 gene [37, 38], it 
is a protein required for progression through the G1 phase of the cell cycle. During the 
G1 phase, it is synthesized rapidly and accumulates in the nucleus, and is degraded as 
the cell enters the S phase. Cyclin D1 is a regulatory subunit of cyclin-dependent 
kinases CDK4 and CDK6. The protein dimerizes with CDK4/6 to regulate the G1/S 
phase transition and entry into the S-phase. 
Cyclin D1 overexpression has been shown to correlate with early cancer onset and 
tumor progression [39] and it can lead to oncogenesis by increasing anchorage-
independent growth and angiogenesis via VEGF production [40]. Cyclin D1 
overexpression can also down-regulate Fas expression, leading to increased 
chemotherapeutic resistance and protection from apoptosis [40], which plays an 
important role in the formation of tumor. 
1.9 Plant polyphenols 
Plant polyphenols is one of the important groups of phytochemicals, it is a 
structural class of mainly natural, but also synthetic or semisynthetic, organic chemicals 




It has been reported that polyphenols exert anticancer effects within human bodies. 
Accumulating evidence suggests that pomegranate polyphenols targets a broad 
spectrum of genes and proteins to suppress cancer growth and progression. The 
anticancer activity of pomegranate can be seen in a variety of cancers include breast 
cancer, colon cancer, liver cancer, skin cancer [42] and lung cancer [43]. Meanwhile, 
Green tea, which has higher concentrations of polyphenols than other teas, has been 
correlated with reduced risk of various malignancies with most data supporting a 
potential protective role in prostate neoplasia [44]. 
1.10 Lignan 
The lignans are a large group of polyphenols found in plants, which also show 
anticancer effects. According to the previous research, lignans can have a protective 
effect on bladder cancer [45], and it can also inhibit breast cancer-mediated bone 
destruction by blocking the vicious cycle between cancer cells, osteoblasts and 
osteoclasts [46]. At the same time, it is reported that a dietary pattern rich in lignans 
decreases the risk of oesophageal cancer [47]. Furthermore, researchers also found that 
higher lignan intakes were associated with lower risks of breast cancer with more 
favorable prognostic characteristics [48]. 
1.11 Arctigenin (ARC) and cancer 
Arctium lappa L. (Asteraceae/Compositae), a biennial plant known as burdock, is 
regarded as an effective Chinese medicine for alleviation of rheumatic pain and fever 
[49]. ARC (C21H24O6; molecular weight: 372.41) is a phenylpropanoid 
dibenzylbutyrolactone lignan which extracted from the Arctium lappa [50]. 




anticancer, and antiviral activities [50]. As a new anticancer agent, ARC exerts anti-
cancer effects in various cancers. In human breast cancer, ARC induces apoptosis of 
estrogen receptor-negative breast cancer cells through the reactive oxygen species 
(ROS)/p38 mitogen-activated protein kinases (MAPKs) pathway and epigenetic 
regulation [51], inhibits the activation of the mTOR pathway, resulting in autophagic 
cell death and decreased ER expression in ER-positive human breast cancer cells [52], 
inhibits metastasis of human breast cancer cells through the downregulation of MMP-
2/-9 and heparanase in MDA-MB-231 cells [53], inhibits STAT3 and exhibits 
anticancer potential in human triple-negative breast cancer therapy [54]. In bladder 
cancer cells, ARC induces cell-cycle arrest and apoptosis [55]. In lung cancer cells, 
ARC enhances chemo-sensitivity of human non-small lung cancer H460 cells  to 
cisplatin through down-regulation of survivin expression and inhibition of the signal 
transducer and activator of transcription 3 (STAT3) signaling pathway [56]. ARC also 
shows pro-apoptotic activity in ovarian cancer cells, which is associated largely with 
modulation of the iNOS/NO/STAT3 axis [57]. The combination of ARC and quercetin 
enhances the anti-proliferative effect in prostate cancer cells [58]. In human colorectal 
cancer, ARC inhibited angiogenesis and migration and invasion of HCT-116 
adenocarcinoma cells through regulating the H1F4A and Wnt/β-catenin pathway [59]. 
ARC also induces apoptosis of HT-29 colon cancer cells by regulating ROS and p38 
MAPK pathways [60]. ARC inhibits lung metastasis of colorectal cancer, in which 
ARC induced cell cycle arrest and apoptosis in CT26 cells through the intrinsic 
apoptotic pathway via MAPKs signaling, controlled EMT through increasing the 
expression of epithelial marker E-cadherin and decreasing the expressions of 
mesenchymal markers; N-cadherin, vimentin, β-catenin, and Snail, as well as inhibited 




MMP-9 expressions [61]. In gastric cancer, the proliferation of SNU-1 and AGS cells 
was significantly inhibited by ARC with cell cycle arrest from G(1) to S phase, which 
was accompanied with changes of cell cycle regulatory proteins such as Rb, cyclin D1, 
cyclin E, CDK4, CDK2, p21Waf1/Cip1 and p15 INK4b [62]. In 
gallbladder cancer cells, ARC decreased the expression of EGFR and led to the 
senescence of cancer cells [60]. ARC can also dose-dependently inhibit the growth of 
oral squamous cell carcinomas, and this effect may be related to down regulation of 
VEGF expression [63]. However, the effect of ARC on metastasis of lung cancer was 
not determined so far. In the present study, we examined whether treatment of ARC 
could repress TGF-β-induced EMT in human lung cancer cells. We found that TGF-β-
induced mesenchymal phenotype was noticeably suppressed by pretreatment with ARC. 
We further found that TGF-β-induced migration and invasion of human lung cancer 
cells were also suppressed by ARC, and we also found that the mechanism of above 
effects of ARC is mainly through suppressing TGF-β-induced phosphorylation of 
SMAD2 and ERK. Thus, ARC could be applied in the new method of treatment toward 










Chapter 2: Materials and Methods 
2.1 Materials 
ARC was purchased from Tocris Bioscience (Bristol, UK) (Fig. 1A). Dulbecco’s 
modified Eagle medium (DMEM) and trypsin were purchased from GE Healthcare 
(Logan, UT, USA). Antibodies for phospho-SMAD2 (CST#3101S), phospho-SMAD3 
(CST#9520S), SMAD2 (CST#5339S), SMAD3 (CST#9513S), E-cadherin (3195P), N-
cadherin (4061S), snail (CST#3879S), active β-catenin (CST#19807), β-catenin 
(CST#9582S), phospho-β-catenin (CST#9561L), phosphorylated ERK (CST#4370P) 
and ERK (CST#9102S) were purchased from Cell Signaling Technology (Beverly, MA, 
USA). Antibodies for β-actin (SC#1616), SMAD4 (SC#H2216), Tubulin (SC#L1813) 
and U1SnRNP (SC#K2613) were purchased from Santa Cruz Biotechnology (Dallas, 
TX, USA). TGF-β (#240-B) was purchased from RD system (Minneapolis, MN, 55413, 
USA). ERK inhibitor PD98059 (#513000) was purchased from Calbiochem (Billerica, 
MA, USA) All other chemicals and reagents were purchased from Fisher Scientific 
(Pittsburgh, PA, USA), unless otherwise specified. 
2.2 Cell culture and treatment 
Human NSCLC cells (A549, H1299, H1703, H358) were maintained at 37°C with 
5% CO2 in media supplemented with 10% fetal bovine serum. The cells were plated 
onto 96-well (for MTT assay), 24-well (for luciferase activity) and 6-well plates (for 
western blot). The cells were treated with TGF-β and different concentrations of ARC 






2.3 Cell Proliferation 
Briefly, the cells were plated onto a 96-well culture plate (1×104 cells/well) with 
media containing different concentrations of ARC for different time periods (0-2 days). 
After removing the media at different time points, 100 ml mixture of serum free media 
and 1 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(5:1) was added into each well then incubated for 3 hours at 37°C in a CO2 incubator. 
Then, MTT dye was extracted using 200 µL of dimethylsulfoxide (DMSO), and the 
absorbance was measured at 540 nm using the microplate reader (Add model). 
2.4 Migration and invasion assay 
For migration assay, the cells were plated onto a 12-well plate and maintained until 
they reach 100% confluence. In a sterile environment (in a biosafety hood), a 200 μl 
pipette tip was used to press firmly against the top of the plate and swiftly make a 
vertical and a horizontal wound through the cell monolayer. A different sized pipette tip 
was used to make the wound size that is desired. Excessive force against the plate was 
avoided with the pipette tip as it may damage the surface. The media and cell debris 
were carefully removed and enough culture media was added slowly with different 
concentrations of ARC against the well wall to cover the bottom of the well and avoid 
detaching additional cells, initial pictures for each well were taken, the culture plate 
was placed in an incubator with 37°C and 5% CO2. After 24 hours, TGF-β was added 
into certain wells, the culture plate was placed in an incubator with 37°C and 5% CO2. 
After 24 hours, pictures for each well were taken. To analyze the results, the distance 
of one side of the wound to the other was measured. 




ng/ml TGF-β on top of the filter membrane in a transwell insert and incubated for 10 
minutes at 37°C and 5% CO2 to allow the cells to settle down. 600 μl of complete media 
which works as chemo-attractant was added very carefully with a pipette into the 
bottom of the lower chamber in a 24-well plate, then complete media was added without 
moving the transwell insert and avoid generating bubbles. Make sure the complete 
media liquid in the bottom well made contact with the membrane in the upper well. The 
system was incubated at 37°C and 5% CO2 for 48 hours. After the incubation, the 
transwell insert was removed from the plate, a cotton-tipped applicator was used as 
many times as needed to carefully remove the media and remaining cells that have not 
migrated from the top of the membrane without damage. 1 ml of 70% ethanol was 
added into a well of a 24-well plate and the transwell insert was placed into the 70% 
ethanol for 10 minutes to allow cell fixation. After that, the transwell insert was 
removed from the 24-well plate and a cotton-tipped applicator was used to remove the 
remaining ethanol from the top of the membrane. The transwell membrane was allowed 
to dry (typically 10-15 minutes). 1 ml of 0.2% crystal violet was added into a well of a 
24-well plate and position the membrane into it for staining at room temperature for 5-
10 minutes. The crystal violet was gently removed from the top of the membrane with 
a pipette tip or cotton tipped applicator, then the membrane was dipped into distilled 
water as many times as needed to remove the excess crystal violet. The transwell 
membrane was allowed to dry for 10-15 minutes. Downside of the transwell membrane 
was observed with microscope and the number of cells in different fields of view was 
counted to get an average sum of cells that have migrated through the membrane toward 




2.5 SDS-PAGE and Western Blot 
Cells were washed with 1×phosphate-buffered saline (PBS), sat on ice for 15 
minutes in radioimmunoprecipitation assay (RIPA) buffer (Boston Bio Products, 
Ashland, MA) supplemented with protease inhibitor cocktail (Sigma Aldrich, St. Louis, 
MO) and phosphatase inhibitor cocktail (Sigma Aldrich) and then harvested. The cell 
lysate was centrifuged at 12,000×g for 15 minutes at 4°C. Protein content was measured 
by the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL). The proteins 
were separated on SDS-PAGE, transferred to nitrocellulose membranes (Osmonics, 
Minnetonka, MN) and blocked in 5% non-fat dry milk in Tris-buffered saline 
containing 0.05% Tween 20 (TBS-T) for 1 hour at room temperature. Membranes were 
probed with specific primary antibodies in 3% Bovine Serum Albumin (Santa Cruz) at 
4°C overnight and then with horse radish peroxidase (HRP)-conjugated 
immunoglobulin G (IgG) for 1 hour at room temperature. Chemiluminescence was 
detected with Pierce ECL Western blotting substrate (Thermo Scientific) and visualized 
by ChemiDoc MP Imaging system (Bio-Rad, Hercules, CA). 
2.6 Transient transfection and reporter gene assay 
Transient transfection was performed using PolyJet reagent (SignaGen 
Laboratories, Ijamsville, MD, USA). The cells (1×105 cells/well) were plated in a 12-
well plate. Media was changed on the next day, then master mixtures of reporter plasmid 
were prepared and dispensed to each well and incubated with cells for 24 hours. After 




media was added, the transfected cells were then treated with or without different 
concentrations of ARC for 24 hours, then the cells were co-treated with TGF-β for 24 
hours. After that, the media was removed, the wells were rinsed with PBS, and 250 µl 
PLB was added into each well, the plate was shaken for 15 minutes at room temperature. 
100 µl LAR was pre-dispensed into luminometer tube. 20 µl PLB lysate mixture was 
transferred into the tube, firefly luciferase activity was measured. 100 µl stop and Glo 
reagent was dispensed and renilla luciferase activity was measured. (Promega, Madison, 
WI, USA). 
2.7 Separation of nuclear and cytoplasmic fraction from cells 
The nuclear and cytoplasmic fractions were isolated separately using an Active 
Motif Nuclear Extract kit (Active Motif, Carlsbad, CA, USA). After the cell pellet was 
acquired, the cells were gently resuspended in 500 µl hypotonic buffer by pipetting up 
and down several times and transferred to a pre-chilled microcentrifuge tube. The cells 
were allowed to swell by incubating for 15 minutes on ice. 25 µl detergent was added 
and vortexed for 10 seconds at the highest setting. The suspension was centrifuged for 
30 seconds at 14000 g in a microcentrifuge tube. The supernatant was collected 
(cytoplasmic fraction) and the pellet was used for nuclear fraction collection. The 
nuclear pellet was resuspended in 50 µl complete lysis buffer by pipetting up and down 
and the suspension was incubated for 30 minutes on ice on a rocking platform set at 
150 rpm. After that, the suspension was vortexed for 30 seconds at the highest setting 
and centrifuged for 10 minutes at 14000 g in a microcentrifuge pre-cooled at 4°C, then 





2.8 Statistical Analysis  
All experiments were conducted in triplicates, and the results were presented as 
mean values ± standard deviations (SD). Significant differences (p<0.05) were 







Chapter 3: Arctigenin (ARC) represses TGF-β-induced epithelial mesenchymal 
transition (EMT) in human lung cancer cells  
3.1 Effect of ARC on viability of A549 
In order to test the viability of the experimental system, we explored if treatment of 
different doses of ARC (0, 12, 25, 50 and 100 μM) leads to toxicity in A549 cells. The 
cells were plated onto 96-well culture plates with media containing different 
concentrations of ARC for different time periods (0-2 days). The media was removed 
at indicated time points, and 1 mg/mL 3-(4,5-dimethylthiazol-2-yl)- 2,5-
diphenyltetrazolium bromide (MTT) was added, and the cells were incubated for 3 
hours at 37°C in a CO2 incubator. Then, MTT dye was extracted using 200 µL of 
dimethylsulfoxide (DMSO), and the absorbance was measured at 540 nm using the 
microplate reader. The result indicated that ARC with concentration below 100 μM had 
no cytotoxicity in A549 cells within 48 hours compared to control group treated with 
vehicle (Fig.1), and the experimental system is viable. 
 
 
Figure 1. Effect of ARC on viability of A549 cells. Effect of different concentrations 
of ARC on A549 cells proliferation was determined using MTT assay. A459 cells were 




























100 µM for 24 hours and 48 hours, respectively. Values were represented as means ± 
SD for triplicates. 
3.2. Effect of ARC on morphological changes of A549 cells during TGF-β-induced 
EMT 
During the EMT, epithelial cells that are closely connected by tight junction turn 
into mesenchymal cells that have a spindle-shaped morphology and interact one another 
through focal adhesion [16]. Therefore, we examined the effect of ARC on TGF-β-
induced EMT in A549 cells through observing the morphological changes of the cells 
after co-treatment with ARC and TGF-β. 
In this experiment, A549 cells were pre-incubated with ARC (12, 25 and 50 µM) 
in serum-free media. After 24 hours, cells were co-incubated with 5 ng/mL TGF-β for 
additional 24 hours. Then the morphology of cells was observed through microscope. 
The result showed that treatment with TGF-β markedly induced the mesenchymal 
phenotype of A549 cells, including elongated and spindle-like shapes. However, this 
morphological change was noticeably suppressed by ARC (Fig.2). 
 
Figure 2. ARC inhibits TGF-β-induced morphological change in A549 cells. A549 
cells were pretreated with ARC for 24 hours and then co-treated with 5 ng/mL TGF-β 
for 24 hours. The cell morphology was observed under microscope. 
3.3. Effects of ARC on motility (migration and invasion) of A549 cells 




increased migration and invasiveness [64]. Therefore, we examined if treatment of 
ARC affects TGF-β-induced migration and invasion of A549 cells. 
First, to determine whether ARC prevents TGF-β-induced migration of A549 cells, 
a wound healing assay was performed by scratching the cell layer prior to TGF-β 
treatment with or without ARC and imaging subsequent cell migration after 48 hours. 
As shown in Fig. 2B, TGF-β-treated cells enhanced cell migration activity compared 
with that of control cells, whereas migration ability of TGF-β-treated cells was 
significantly inhibited by ARC in a dose-dependent manner (Fig.3A). Second, we 
examined whether ARC prevents TGF-β-induced invasion of A549 cells. The cells 
were cultured in an invasion chamber in Transwells (inner chamber) and treated with 
TGF-β and different doses of ARC for 24 hours in the Transwells. The invasive cells, 
presented on the lower surface of the chamber, were then stained and imaged, and 
invasion ability was measured through counting the number of invasive cells. The result 
showed that TGF-β treatment promoted cell invasion ability by approximately 3.5-fold 
compared with that of the control cells, and this effect was significantly suppressed by 
ARC (Fig.3B and 3C). All taken together, these results demonstrated that ARC prevents 





Figure 3. ARC inhibits TGF-β-induced migration and invasion in A549 cells. 
(A) A549 cells were pretreated with ARC for 24 hours and then co-treated with 5 ng/mL 
TGF-β for 24 hours. The cells were photographed under microscope 48 hours after 
scratching. (B) A549 cells were treated with 50 μM ARC and 5 ng/ml TGF-β for 48 
hours. The invasion was measured using Matrigel invasion assay. In vitro invasiveness 
of A549 cells were imaged and measured by counting cells that migrated through the 
extracellular matrix layer of invasion chambers. (C) The graph represents mean ± SD 
for five replicates. *p<0.05 versus control. 
3.4 The effect of ARC and TGF-β on expression of VEGF and cyclin D1 in A549 cells 
VEGF and Cyclin D1 are closely involved in tumorigenesis of lung cancer 
(References). Therefore, in order to investigate potential mechanism, we examined the 
effect of ARC TGF-β on expression of VEGF and Cyclin D1 in A549 cells. The result 







Figure 4. ARC and TGF-β have no effect on the expression of VEGF and Cyclin 
D1 in A549 cells. A549 cells were pretreated with the indicated concentration of ARC 
for 24 hours and then stimulated with TGF-β (5 ng/mL) for 24 hours. Western Blot was 
performed to measure the expression of VEGF and Cyclin D1. 
3.5 ARC’s effect on TGF-β-induced phosphorylation of SMAD2/3 
TGF-β-induced EMT is mediated through SMAD signaling pathways. After TGF-
β stimulation, SMAD2 and SMAD3 is phosphorylated, translocated into nucleus, 
formed SMAD2/3 complex, and then induce the EMT [65]. Therefore, we explored the 
mechanism of ARC’s effect on TGF-β-induced EMT through examining its effect on 
TGF-β-induced phosphorylation of SMAD2/3. 
The result showed that TGF-β treatment promoted the phosphorylation of SMAD2, 
which was significantly decreased in the presence of ARC (Fig.5A). This result 
indicated that ARC prevented the TGF-β-induced phosphorylation of SMAD2, by 
which to inhibit TGF-β-induced EMT in A549 cells. However, although TGF-β 
treatment also promoted the phosphorylation of SMAD3, it was not suppressed by ARC. 
In addition, we found that ARC also inhibited TGF-β-induced phosphorylation of 
SMAD2 in another three lung cancer cell lines H1299, H1703 and H358 (Fig.5B), 




EMT in lung cancer cells. 
 
Figure 5. ARC’s effects on TGF-β-induced phosphorylation of SMAD2/3. 
(A) A549 cells were pretreated with the indicated concentration of ARC for 24 hours 
and then stimulated with TGF-β (5 ng/mL) for 30 minutes. Western blot was performed 
to measure phospho- and total SMAD2/3. (B) Three different types of human NSCLC 
cells (H1299, H1703, H358) were pre-treated with ARC (50 µM) for 24 hours and then 
co-treated with TGF-β (5 ng/mL) for 30 minutes. Western blot was performed to 
measure phospho- and total SMAD2. 
3.6 ARC inhibits expression of N-cadherin and snail, rescues the decrease of E-cadherin 
expression during TGF-β-induced EMT. 
During the EMT, epithelial cells lose E-cadherin expression and turn into 
mesenchymal cells that overexpress N-cadherin. Therefore, by examining ARC’s effect 
on TGF-β-induced change of expression of E-cadherin and N-cadherin, we can further 
verify ARC’s effect on TGF-β-induced EMT in A549 cells. 
The results showed that E-cadherin expression was decreased significantly by TGF-
β treatment, whereas N-cadherin expression increased in TGF-β-treated A549 cells 
compared with that in control cells. In contrast, ARC treatment remarkably reversed 




Furthermore, downregulation of E-cadherin in the TGF-β-induced EMT process can 
be induced by transcriptional repressor, snail [66]. Thus, we also investigated whether 
ARC represses snail expression stimulated by TGF-β. As a result, expression of snail 
increased prominently in TGF-β-treated A549 cells compared with that in control cells. 
However, snail expression decreased following ARC treatment in a dose-dependent 
manner (Fig.6). Taken together, these results strongly suggested that ARC plays an 
important role in suppressing TGF-β-induced EMT in A549 cells by rescuing TGF-β-
induced suppression of E-cadherin expression and suppressing TGF-β-induced 
expression of N-catenin and snail. 
 
Figure 6. ARC inhibits expression of N-cadherin and snail, rescues the decrease of 
E-cadherin expression during TGF-β-induced EMT. A549 cells were pretreated 
with the indicated concentration of ARC for 24 hours and then stimulated with TGF-β 
(5 ng/mL) for 24 hours. Western Blot was performed to measure expression of the E-





3.7 ARC inhibits TGF-β-induced phosphorylation of SMAD2, expression of N-
cadherin and snail, and rescues E-cadherin expression in time-dependent manner. 
To investigate the time-sequential changes of EMT-related genes, A549 cells were 
pre-treated with ARC for 24 hours, and then co-treated with TGF-β for 15 minutes, 30 
minutes, 1 hour, 8 hours and 24 hours respectively. Western Blot was performed to 
measure phosphorylation of SMAD2 and expression of E-cadherin, N-cadherin and 
snail. 
The result showed that ARC exerts its inhibitory effect on TGF-β-induced 
phosphorylation of SMAD2 from 15 minutes to 1 hour. For ARC’s rescuing the 
expression of E-cadherin, the time point is 24 hours, and ARC can inhibit TGF-β-
induced expression of N-cadherin and snail from 15 minutes to 8 hours and 15 minutes 
to 24 hours respectively (Fig.7). 
 
Figure 7. ARC inhibits TGF-β-induced phosphorylation of SMAD2, expression of 
N-cadherin and snail, and rescues E-cadherin expression in time-dependent 




hours and then stimulated with TGF-β (5 ng/mL) for a series of time periods (15 
minutes, 30 minutes, 1 hour, 8 hours and 24 hours). Western Blot was performed to 
measure expression of phospho-SMAD2/3, E-cadherin, N-cadherin, snail and β-actin. 
3.8 ARC’s effect on TGF-β signaling pathway measured by transfecting the 
reporter p3TP-Lux. 
To test transcriptional activity of TGF-β signaling, we did report gene analysis 
using p3TP-Lux reporter gene containing SMAD-binding sites at 5’-flaking region of 
luciferase genes. The result of reporter gene p3TP-Lux transfection and subsequent 
luciferase assay showed that ARC does inhibit TGF-β signaling pathway (Fig.8), which 
is consistent to the above results. 
 
Figure 8. ARC’s effect on TGF-β signaling pathway measured by transfecting the 
reporter p3TP-Lux. A549 cells were transfected with the p3TP-Lux reporter, then 
pretreated with the indicated concentration of ARC for 24 hours and then stimulated 
with TGF-β (5 ng/mL) for 24 hours. Luciferase activity was measuring as indicated in 





3.9 ARC inhibits translocation of phospho-SMAD2/3 during TGF-β-induced EMT. 
During TGF-β-induced EMT, the activated TGF-β receptor phosphorylates 
SMAD2 and SMAD3, which then complex with SMAD4 and translocate to the nucleus 
[67]. Therefore, we examined the ARC’s effect on translocation of phospho-SMAD2/3 
during TGF-β-induced EMT, by which to further verify ARC’s effect on TGF-β-
induced EMT. 
In this experiment, A549 cells were exposed to ARC for 24 hours and then co-
treated with 5 ng/mL TGF-β for 6 hours. Cells were harvested, cytoplasm protein and 
nuclear protein were extracted separately and subjected to Western Blot analysis. The 
expression of tubulin and U1snRNP were used as markers for cytoplasmic and nuclear 
protein, respectively. 
The result showed that ARC effectively inhibits the TGF-β-induced translocation 
of phosphorylated SMAD2 and SMAD3 from cytoplasm to nucleus (Fig.9), which 





Figure 9. ARC inhibits translocation of phospho-SMAD2/3 during TGF-β-induced 
EMT. A549 cells were exposed to ARC for 24 hours and then co-treated with 5 ng/mL 
TGF-β for 6 hours. Cells were harvested, cytoplasm and nuclear protein were extracted 
separately and subjected to Western Blot analysis for phosphorylated and total 
SMAD2/3, tubulin (cytosolic marker) and U1snRNP (nuclear marker). 
3.10 ARC inhibits TGF-β-induced phosphorylation of ERK 
Since it is reported that ERK is responsible for activation of SMAD2 after TGF-β 
treatment [68], we proposed that ARC may exert the effect of suppressing TGF-β-
induced EMT through inhibiting TGF-β-induced phosphorylation of ERK other than 
inhibiting TGF-β-induced phosphorylation of SMAD2. In order to verify this proposal, 
we examined the effect of ARC on TGF-β-induced phosphorylation of ERK in A549 
cells. 
The result showed that ARC does prevent the TGF-β-induced phosphorylation of 
ERK (Fig.10), indicating that ARC suppress TGF-β-induced EMT through inhibiting 
TGF-β-induced activation of ERK. 
 
Figure 10. ARC inhibits TGF-β-induced phosphorylation of ERK. A549 cells were 
exposed to ARC for 24 hours and then co-treated with 5 ng/mL TGF-β for 30 minutes. 




3.11 ARC inhibits transcriptional activity of β-catenin. 
It is reported that β-catenin, which is a multifunctional protein involved in two 
independent processes: cell to cell adhesion and signal transduction, is released from 
the E-cadherin complexes into the cytoplasm during EMT where it interacts with other 
proteins, raising the possibility that β-catenin signaling contributes to EMT [69]. In 
addition, β-catenin functions as a critical downstream transcriptional activator in the 
Wnt signaling pathway, and it may translocate into the nucleus where it functions as a 
cofactor of the T-cell factor family of transcription factors to drive the expression of 
important cell cycle proteins, oncogenes, and proteases including c-myc, cyclin-D1 
[70], and MMP-7 [71]. In summary, β-catenin plays an important role in EMT and its 
related cell signaling pathway. Therefore, we suppose that ARC may inhibit 
transcriptional activity of β-catenin, by which to suppress TGF-β-induced EMT in 
A549 cells. 
In this experiment, we transfected TOP/FOP flash luciferase reporter plasmid into 
A549 cells and then co-treated with TGF-β in the absence or presence of 50 µM of 
ARC. The result of the subsequent luciferase assay showed that TGF-β increased 
transcriptional activity of β-catenin by 2.5-fold and 1.8-fold in the absence and presence 
of ARC, respectively (Fig.11), which indicates that ARC suppresses TGF-β-induced 
increasing of transcriptional activity of β-catenin, which is also one of the mechanisms 





Figure 11. ARC inhibits transcriptional activity of β-catenin. A549 cells were 
transfected with TOP/flash containing β-catenin/TCF binding site or FOP/flash 
(negative control) and then co-treated with TGF-β in the presence or absence of ARC 
for 24 hours. The luciferase activity was measured and expressed as mean ± SD for 

























Chapter 4: Discussion, propose mechanism and conclusion 
4.1 Discussion 
Lung cancer is one of the most common cancers in the world, it is a leading cause 
of cancer death in men and women in the United States. Overall, 17.4% of people in 
the United States diagnosed with lung cancer survive five years after the diagnosis 
while outcomes on average are worse in the developing countries due to less access to 
diagnosis and medical treatment [4]. 
One of the most important reasons of lung cancer’s malignancy, poor prognosis 
and high death rate is metastasis. Metastasis is the most fatal characteristics of 
malignancy tumor, which accounted for more than 90% of tumor-related mortality. 
Distant organ or tissue metastasis is a sign of poor prognosis in patients with lung 
cancer. Tumor cells metastasis is a very complex process including tumor cell 
transformation, growth, angiogenesis, invasion, dissemination and survival in the 
circulation, and subsequent adhesion and colonization the secondary organ or tissue [7]. 
During metastasis, TGF-β-induced EMT of cancer cells plays an important role. 
EMT is the process that epithelial cells lose their cell polarity and cell-cell adhesion, 
and gain migratory and invasive properties to become mesenchymal stem cells [8]. 
During this process, cancer cells gain increased invasive property, by which to break 
through the basement membrane and enter the bloodstream through intravasation. Later, 
when these circulating tumor cells (CTCs) exit the bloodstream to form micro-
metastases, they undergo MET for clonal outgrowth at these metastatic sites. Thus, 
EMT and MET form the initiation and completion of the invasion-metastasis cascade 
[72]. At this new metastatic site, the tumor may undergo other processes to optimize 




lung cancer. Increased levels of PD-L1 suppresses the immune system which allows 
the cancer to spread more easily [73]. 
As mentioned above, TGF-β is one of the most important stimulants of EMT. 
When TGF-β ligands bind to their type II and type III receptors (TGF-β RII and TGF-
β RIII), which causes recruitment and phosphorylation of the type I receptor (TGF-β 
RI). This activates various signaling pathways, including those mediated by SMAD2/3, 
Ras, and PI3K (simplified here), which activate transcription factors that induce the 
expression of genes encoding EMT-inducing transcription factors. At the surface of the 
cell, TACE cleaves the intracellular domain of TGF-β RI, which can then act as a 
transcriptional regulator to mediate EMT. Additionally, the Par3–Par6–aPKC (atypical 
PKC) complex also associates with TGF-β Rs at the cell membrane and is involved in 
cytoskeletal remodeling to promote the mesenchymal phenotype. SMAD-independent 
pathways (such as through PI3K and ILK) can activate Akt, which in turn can inhibit 
the function of GSK-3β, a kinase that inhibits nuclear translocation of Snail and β-
catenin. Inhibition of SMAD signaling is mediated by SMAD6/7, which prevent the 
binding and phosphorylation of SMAD2/3 at TGF-β Rs, and by Smurf2, which is 
known to degrade the activated complex of SMAD2/3/4 [74]. 
Arctigenin (ARC) is an active ingredient of Arctium lappa and exhibits anti-
inflammatory [75], anti-viral [76] and anti-cancer [55] activity in various types of 
cancer cells. For example, ARC inhibits the growth of colon cancer [77], ovarian cancer 
[57], hepatocellular carcinoma [78], gastric cancer [62], breast cancer [51], and bladder 
cancer [55]. The reliable mechanisms include induction of apoptosis [79] or cell cycle 
arrest [80] through downregulating STAT3 (signal transducer and activator of 
transcription-3)/survivin signaling [57], phosphatidylinositol-3-kinase (PI3K)/AKT 




kinase) pathway [51], and phosphorylation of retinoblastoma (Rb) [62]. Recently a few 
studies reported anti-metastatic activity of ARC in breast cancer cells [53, 81] and colon 
cancer [61]. 
Here, for the first time, we revealed that ARC significantly suppresses the TGF-β-
induced migration, invasion and EMT of NSCLC cells. Our results showed that ARC 
inhibited TGF-β-induced EMT development in A549 lung cancer cells at 
concentrations of 25 µM and 50 µM, while no toxic effects toward the cells was 
observed in these concentrations. Moreover, we found that ARC inhibited TGF-β-
induced phosphorylation of SMAD2 and translocation of SMAD2/3 in the TGF-β-
induced EMT, as well as TGF-β-induced phosphorylation of ERK, suggesting that ARC 
prevents EMT and metastasis in the TGF-β-induced signaling pathway by inhibiting 
SMAD2 phosphorylation as well as ERK phosphorylation. We also found that the 
increase in snail expression and transactivation of β-catenin via the TGF-β-induced 
EMT was also inhibited by ARC. These results are consistent with the inverse 
















As shown above, regarding to cellular and molecular event, TGF-β first binds to 
type II receptor which leads to recruitment and phosphorylation of the type I receptor. 
The activated type I receptor subsequently induces phosphorylation of SMAD2 and 
SMAD3 (R-SMADs) and form heterodimeric complexes with a SMAD4 (co-SMAD). 
The complex of SMAD2/3/4 translocate into the nucleus and binds to SMAD response 
element (SRE) on the promoter of their specific target genes, and mediates EMT [19]. 
According to our results, ARC can suppress TGF-β-induced phosphorylation of 





On the other hand, the activated type I receptor subsequently induces 
phosphorylation of ERK [82], which is required for accumulation of β-catenin in the 
nucleus [83], where it binds to LEF/TCF transcription factors, displacing co-repressors 
and recruiting additional co-activators to Wnt target genes such as Cyclin D1 and 
MMP-7 [84], by which to alter the cells’ biological features. For example, increased 
ability of proliferation, migration, survival, growth, and decreased adhesion property, 
which are all key factors in triggering and development of cancer. Additionally, β-
catenin cooperates with several other transcription factors to regulate specific targets. 
Moreover, Wnt signaling has also been shown to promote nuclear accumulation of other 
transcriptional regulator implicated in cancer, such as TAZ and Snail1. 
Based on our results, ARC inhibits TGF-β-induced phosphorylation of ERK and 
SMAD2, by which to exert its anti-cancer effects against human lung cancer cells A549. 
4.3 Conclusion 
We demonstrated that ARC suppresses progression and metastasis of A549 cells 
through suppressing TGF-β-induced EMT, with the mechanisms of inhibiting TGF-β-
induced phosphorylation of SMAD2 and ERK, suppressing TGF-β-induced 
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